HemCon Medical Technologies, Inc. Signs Exclusive Partnership for the Development and Distribution of Synaero(TM) Hemostatic Gel for ENT Procedures

PORTLAND, Ore.--(BUSINESS WIRE)--HemCon Medical Technologies (“HemCon”), a global innovative developer of advanced medical technologies and products, has recently partnered with ENTrigue Surgical, Inc. (“ENTrigue”), a leading provider of medical devices and therapies for surgeries of the Ear, Nose and Throat, to develop and distribute HemCon’s latest breakthrough product, a hemostatic surgical gel. Synaero Hemostatic Gel, based on HemCon’s proprietary oxidized cellulose platform, is a hemostatic gel to be used during and after ENT surgical procedures to control bleeding, minimize edema and prevent adhesions.

Back to news